NUVAXOVID arrives ready to use in pre-filled syringes, with no freezing or thawing needed1
Ready to use—no dilution, mixing, or thawing required
Ships in a carton of 10 pre-filled syringes, each containing 1 dose of 0.5 mL
Store in a standard refrigerator
Store pre-filled syringes between 2 to 8 °C (36 to 46 °F)
Do not freeze. Protect from light.
Store in original carton to protect from light.
Follow the recommended dosing schedule when administering NUVAXOVID1-3
For patients aged 65+
Vaccinated with primary series of NUVAXOVID or with any other COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose at least 2 months after receipt of the previous COVID-19 vaccine dose1
- ACIP recommends patients should receive an additional dose 6 months after the previous dose (minimum interval of 2 months)2
Not previously vaccinated with any COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose1
- ACIP recommends patients should receive an additional dose 6 months after the previous dose (minimum interval of 2 months)2
For patients aged 12-64 with ≥1 underlying condition
Vaccinated with primary series of NUVAXOVID or with any other COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose at least 2 months after receipt of the previous COVID-19 vaccine dose1,4
Not previously vaccinated with any COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose1,4
Are your high-risk patients eligible for NUVAXOVID?
The NUVAXOVID pivotal trial included patients who were high risk for COVID-19 due to underlying conditions, including chronic lung disease, cardiovascular disease, chronic liver disease, severe obesity, and diabetes.1
You can access the FDA's policy position on COVID-19 vaccination to see the list of medical conditions that increase risk of severe COVID-19. For further information. consult your national and local health authorities.
NUVAXOVID is the only protein-based, non-mRNA COVID-19 vaccine option you can offer to eligible patients regardless of the previous COVID-19 vaccines they received.1
INDICATION
References
1. NUVAXOVID. Prescribing Information. Novavax, Inc. 2. Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024-2025 COVID-19 vaccine for adults aged ≥65 years and persons aged ≥6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(49):1118-1123. 3. Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2024 Sep 19;73(37):819-824. doi:10.15585/mmwr. mm7337e2 4. 2025–2026 COVID-19 vaccination guidance. Centers for Disease Control and Prevention. Accessed February 10, 2026. https://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html
